Radiopharmaceutical Therapy Workshop 2025

Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies. This onDemand workshop focuses on clinical indications, difficult cases, medical physics considerations, development of standard operating procedures for clinical implementation, billing, and safe theranostic delivery practices. Specifically, Radium-223, Lutetium-177 dotatate and Lutetium-177 PSMA-617 are discussed. The activity includes didactic presentation from physician experts from radiation oncology, nuclear medicine, medical oncology and medical physicists, with question and answer sessions to discuss practice implementation in various clinical settings (i.e., academic hospital vs. community practice, nuclear medicine vs. radiation oncology). The purpose of the activity is to increase physician, physicist and administration understanding on how to effectively and safely conduct a radiopharmaceutical program at their respective institutions. 

This activity is available from December 1, 2025, through 11:59 p.m. Eastern time on December 31, 2026.

This activity was originally presented and recorded at the 2025 ASTRO Annual Meeting. 

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, physicists, nurses, diagnostic radiologists, radiation therapists and radiation dosimetrists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the relevant principles of physics, pharmacology and radiobiology for radiopharmaceutical therapies (RPTs).
  • Identify clinical indications for RPTs that are currently approved for clinical use.
  • Identify logistical steps and common challenges in implementing RPT use in their own practice.
     
Course summary
Available credit: 
  • 4.50 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 4.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 4.50 Certificate of Attendance
    This activity was designated for 4.50 AMA PRA Category 1 Credit™.
Course opens: 
12/01/2025
Course expires: 
12/31/2025
Cost:
$379.00
Rating: 
0

The workshop onDemand includes the following presentations:

  1. Radiobiology Update and Educational Resources - Ana Kiess, MD, PhD
  2. Bench to Clinical Trials: Considerations for Theranostics Translation - Henry VanBrocklin, PhD
  3. Standard Operating Procedures for Radiopharmaceutical Therapies - Jacqueline Zoberi, PhD
  4. Administrative and Billing Processes for a RPT Program - Tina Visser, BS
  5. Clinical Pearls from an Academic RO:NM Partnership - Hyun Kim, MD
  6. Panel Q&A Part 1
  7. Integrating Lu177-PSMA with Other Systemic Options for Advanced Prostate Cancer - William Oh, MD
  8. Incorporating Theranostics into Prostate Cancer Clinical Practice - Bridget Koontz, MD, FASTRO
  9. RLT for NET - Ravi Shridhar, MD, PhD
  10. Integrating RPT with External Beam Treatment - Neil Taunk, MD, MS
  11. Newer Isotopes and Future Indications for RPT - Michael Folkert, MD, PhD
  12. Panel Q&A Part 2

Moderators:

  • Richard Glenn Stock, MD, is employed by Icahn School of Medicine at Mount Sinai. 
  •  

Speakers:

  • Ana P. Kiess, MD, PhD, is employed by the Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine. Dr. Kiess receives clinical trial funding from Bayer, Novartis, Merck, Lantheus, and Convergent. Dr. Kiess is a volunteer consultant/speaker/advisor for Novartis, POINT, and PMH. 
  • Hyun Kim, MD, is employed by Washington University School of Medicine. Dr. Kim receives research funding, speaker fees, and is a consultant for Varian. Dr. Kim also consults for Novartis. Dr. Kim has limited liability company interest with GlobalART as the Founder/CEO. 
  • Neil K. Taunk, MD, MS, is employed by the University of Pennsylvania. Dr. Taunk has relationships with Boston Scientific, Varian Medical Systems, Point BioPharma (Lilly), Novartis, GE Healthcare, Telix Pharmaceuticals, GenMab Pharmaceuticals. Dr. Taunk receives research funding from Varian Medical Systems, Therapanacea AI, Basser Center for BRCA, RSNA, NIH. Dr. Taunk is a member of the following committees: CAMPEP Board of Governors, ASTRO Radiopharmaceutical Committee, American Radium Society Radiopharmaceutical Committee. 
  • William Oh, MD, is employed by Icahn School of Medicine at Mount Sinai. Dr. Oh is the Chair of the National Prostate Cancer Roundtable at the American Cancer Society. Dr. Oh consults for Abbott, Astra Zeneca, Cytogen, Novartis, Sumitomo, and VieCure. Dr. Oh has equity in Archetype Therapeutics, GeneDx, NTx Bio, and Previvor Care.
  • Ravi Shridhar, MD, PhD, is employed by Advent Health Cancer Institute and serves as the AU Program Director for Theranostics. Dr. Shridhar is a speaker, consultant, proctor for Boston Scientific and a speaker for AstraZeneca. 

The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee and the 2024 ASTRO Annual Meeting Education and Steering Committees had control over the content of this activity. All relevant relationships have been mitigated.

Disclosure link: 
ASTRO Education Committee

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

Available Credit

  • 4.50 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 4.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 4.50 Certificate of Attendance
    This activity was designated for 4.50 AMA PRA Category 1 Credit™.

Price

Cost:
$379.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.

  • Nonmember: $379
  • Member: $249
  • Member-in-Training: $129
  • Student/Graduate Student/PGY-1 Member: $129
  • Postdoctoral Fellow Member: $129

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until December 31, 2026, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.